Global Cardiovascular Partnering Deal Trends, Players and Financials 2012-2018 - ResearchAndMarkets.com

DUBLIN--()--The "Global Cardiovascular Partnering 2012-2018: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.

Global Cardiovascular Partnering 2012 to 2018 provides the full collection of Cardiovascular disease deals signed between the world's pharmaceutical and biotechnology companies since 2012.

  • Trends in Cardiovascular partnering deals
  • Financial deal terms for headline, upfront and royalty by stage of development
  • Cardiovascular partnering agreement structure
  • Cardiovascular partnering contract documents
  • Top Cardiovascular deals by value
  • Most active Cardiovascular dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Cardiovascular disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Cardiovascular deals.

The report presents financial deal terms values for Cardiovascular deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

In addition, a comprehensive appendix is provided with each report of all Cardiovascular partnering deals signed and announced since 2012. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Cardiovascular partnering and dealmaking since 2012.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Cardiovascular technologies and products.

Report scope

Deal trends, players and financials includes:

  • Trends in cardiovascular dealmaking in the biopharma industry since 2012
  • Analysis of cardiovascular deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to over 1,000 cardiovascular deal records
  • The leading cardiovascular deals by value since 2012

Deal trends, players and financials, the available deals are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Cardiovascular dealmaking

Chapter 3 -Financial deal terms for Cardiovascular partnering

Chapter 4 - Leading Cardiovascular deals and dealmakers

Chapter 5 - Cardiovascular contract document directory

Chapter 6 - Cardiovascular dealmaking by therapeutic target

For more information about this report visit https://www.researchandmarkets.com/research/5kpb5z/global?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Cardiovascular Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Cardiovascular Drugs